Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agile Therapeutics Inc (NQ: AGRX )

0.2300 -0.0019 (-0.82%)
Streaming Delayed Price Updated: 3:55 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 429,323
Open 0.2400
Bid (Size) 0.2100 (32)
Ask (Size) 0.2101 (186)
Prev. Close 0.2319
Today's Range 0.2180 - 0.2429
52wk Range 0.1750 - 11.40
Shares Outstanding 46,538,250
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers DiamondHead Holdings Corp. (NASDAQ: DHHC) shares jumped 104.2% to $21.15. DiamondHead entered into convertible note purchase agreement dated March 21, 2023. 
Via Benzinga
Agile Therapeutics's Return On Capital Employed Insights
 
Via Benzinga

Performance

YTD
+6.14%
+6.14%
1 Month
-4.13%
-4.13%
3 Month
+15.29%
+15.29%
6 Month
-19.07%
-19.07%
1 Year
-97.60%
-97.60%

More News

Read More
Why Agile Therapeutics Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women
Via TheNewswire.com
HC Wainwright & Co. Maintains Buy Rating for Agile Therapeutics: Here's What You Need To Know
Via Benzinga
Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via Globe NewsWire
Agile Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on Wednesday, March 22, 2023
From Agile Therapeutics, Inc.
Via Globe NewsWire
Agile Therapeutics Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
From Agile Therapeutics, Inc.
Via Globe NewsWire
Agile Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation
From Agile Therapeutics, Inc.
Via Globe NewsWire
Agile Therapeutics Announces Distribution of Series C Preferred Stock to its Holders of Common Stock
From Agile Therapeutics, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women
Via News Direct
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women
Via Benzinga
Agile Therapeutics Provides Updates on 2022 Twirla Performance and 2023 Commercial Plan
From Agile Therapeutics, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Ardelyx To Rally 160%? Here Are 10 Other Price Target Changes For Friday
Via Benzinga
This Biotech Company is Pursuing Positive Cash Flow In 2023
Via TheNewswire.com
This Biotech Company is Pursuing Positive Cash Flow In 2023
Via News Direct
This Biotech Company is Pursuing Positive Cash Flow In 2023
Via Benzinga
Agile Therapeutics To Present At The Upcoming RHK Capital Disruptive Growth Conference
From Agile Therapeutics, Inc.
Via Globe NewsWire
Women’s Healthcare Company Agile Therapeutics Says It Believes It Has An Effective Business Plan In Place For Growth And Generating Positive Cash Flow
Via News Direct
Women’s Healthcare Company Agile Therapeutics Says It Believes It Has An Effective Business Plan In Place For Growth And Generating Positive Cash Flow
Via TheNewswire.com
Women's Healthcare Company Agile Therapeutics Says It Believes It Has An Effective Business Plan In Place For Growth And Generating Positive Cash Flow
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.